Alvotech Prices $151.85M Combined Public Offering and Private Placement at $3.75 Per Share

summarizeSummary

Alvotech has priced a combined public offering and concurrent private placement, raising $143.72 million in net proceeds by issuing 40.49 million shares at $3.75 each. This substantial capital raise, while dilutive, is intended to fund biosimilar development and general corporate needs.

check_boxKey Events · Financing and Capital Events · ALVO

• Public Offering Priced

  Alvotech is offering 22,666,667 ordinary shares at a public offering price of $3.75 per share, generating gross proceeds of approximately $85.0 million.

• Concurrent Private Placement

  The company entered into agreements for a concurrent private placement of 17,826,666 ordinary shares at the same $3.75 per share price, for gross proceeds of approximately $66.85 million.

• Substantial Capital Raise

  The combined offerings are expected to generate total net proceeds of approximately $143.72 million, providing significant capital for the company.

• Significant Share Dilution

  The issuance of 40,493,333 new shares represents a dilution of approximately 12.97% to existing shareholders, based on shares outstanding as of March 31, 2026.

auto_awesomeAnalysis · ALVO · Life Sciences

This filing finalizes the terms and pricing of the previously announced public offering and concurrent private placement. The company is raising a substantial $143.72 million in net proceeds by issuing 40.49 million new shares at $3.75 per share, a discount to the prior day's closing price of $4.24. This capital infusion, representing nearly 12% of the company's market capitalization, is crucial for funding biosimilar development and general corporate purposes, especially given recent regulatory challenges. However, it will result in significant dilution for existing shareholders.